Literature DB >> 28237643

Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer.

Hyoung Woo Kim1, Jong-Chan Lee1, Kyu-Hyun Paik1, Jingu Kang1, Young Hoon Kim2, Yoo-Seok Yoon3, Ho-Seong Han3, Jaihwan Kim1, Jin-Hyeok Hwang4.   

Abstract

BACKGROUND: The adjunctive role of magnetic resonance imaging of the liver before pancreatic ductal adenocarcinoma has been unclear. We evaluated whether the combination of hepatic magnetic resonance imaging with multidetector computed tomography using a pancreatic protocol (pCT) could help surgeons select appropriate candidates and decrease the risk of early recurrence.
METHODS: We retrospectively enrolled 167 patients in whom complete resection was achieved without grossly visible residual tumor; 102 patients underwent pCT alone (CT group) and 65 underwent both hepatic magnetic resonance imaging and pCT (magnetic resonance imaging group).
RESULTS: By adding hepatic magnetic resonance imaging during preoperative evaluation, hepatic metastases were newly discovered in 3 of 58 patients (5%) without hepatic lesions on pCT and 17 of 53 patients (32%) with indeterminate hepatic lesions on pCT. Patients with borderline resectability, a tumor size >3 cm, or preoperative carbohydrate antigen 19-9 level >1,000 U/mL had a greater rate of hepatic metastasis on subsequent hepatic magnetic resonance imaging. Among 167 patients in whom R0/R1 resection was achieved, the median overall survival was 18.2 vs 24.7 months (P = .020) and the disease-free survival was 8.5 vs 10.0 months (P = .016) in the CT and magnetic resonance imaging groups, respectively (median follow-up, 18.3 months). Recurrence developed in 82 (80%) and 43 (66%) patients in the CT and magnetic resonance imaging groups, respectively. The cumulative hepatic recurrence rate was greater in the CT group than in the magnetic resonance imaging group (P < .001).
CONCLUSION: Preoperative hepatic magnetic resonance imaging should be considered in patients with potentially resectable pancreatic ductal adenocarcinoma, especially those with high tumor burden.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28237643     DOI: 10.1016/j.surg.2016.12.038

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT.

Authors:  Sun Kyung Jeon; Jeong Min Lee; Ijin Joo; Dong Ho Lee; Su Joa Ahn; Hyunsik Woo; Myoung Seok Lee; Jin-Young Jang; Joon Koo Han
Journal:  Eur Radiol       Date:  2018-01-19       Impact factor: 5.315

2.  Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios inversely correlate to clinical and pathologic stage in patients with resectable pancreatic ductal adenocarcinoma.

Authors:  Alejandro Recio-Boiles; Aparna Nallagangula; Summana Veeravelli; Jessica Vondrak; Kathylynn Saboda; Denise Roe; Emad Elquza; Ali McBride; Hani M Babiker
Journal:  Ann Pancreat Cancer       Date:  2019-06-11

3.  CT and MRI of pancreatic cancer: there is no rose without a thorn!

Authors:  N Kartalis
Journal:  Eur Radiol       Date:  2018-05-23       Impact factor: 5.315

Review 4.  [Radiologic Evaluation for Resectability of Pancreatic Adenocarcinoma].

Authors:  Shin Hye Hwang; Mi-Suk Park
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-03-31

5.  Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).

Authors:  Lilian Schwarz; Dewi Vernerey; Jean-Baptiste Bachet; Jean-Jacques Tuech; Fabienne Portales; Pierre Michel; Antonio Sa Cunha
Journal:  BMC Cancer       Date:  2018-07-24       Impact factor: 4.430

6.  Staging laparoscopy with ultrasound and near-infrared fluorescence imaging to detect occult metastases of pancreatic and periampullary cancer.

Authors:  H J M Handgraaf; B G Sibinga Mulder; S Shahbazi Feshtali; L S F Boogerd; M J M van der Valk; A Fariña Sarasqueta; R J Swijnenburg; B A Bonsing; A L Vahrmeijer; J S D Mieog
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.